16. Eli Lilly (LLY)
Number of Hedge Funds: 137 (2025Q4)
Number of Hedge Funds: 114 (2025Q3)
Eli Lilly (LLY) is positioned as a dominant institutional favorite, buoyed by its leadership in the obesity and metabolic health markets. While the stock has seen a massive run-up to the $1,040 level, the “smart money” is doubling down on its long-term growth potential.
1. High-Conviction Hedge Fund Accumulation
Elite managers are aggressively increasing their exposure, signaling that they believe the peak of the GLP-1 (Zepbound/Mounjaro) cycle is still far off.
- Marshall Wace (Paul Marshall & Ian Wace): Made a massive high-conviction move, increasing its position by a staggering 641% to over 1.2 million shares, a stake valued at $1.3 billion.
- Fisher Asset Management (Ken Fisher): Maintained its steady conviction with a 4% increase, holding 4.6 million shares valued at nearly $4.95 billion.
- Citadel (Ken Griffin): Is playing the volatility with massive options exposure. While Griffin trimmed his “Call” and “Put” positions slightly (by 4% and 7% respectively), he still holds over $4.6 billion in combined options value, suggesting he is betting on significant price swings at these record levels.
2. Analyst Upgrades & The “Obesity Leadership” Thesis
Wall Street is locked into a race to raise price targets as Lilly continues to expand its clinical data moat.
- Barclays & RBC Capital Initiations: In late February 2026, both firms initiated/reiterated coverage with massive targets. Barclays set a $1,350 price target (Overweight), while RBC Capital set it at $1,250 (Outperform), both citing Lilly’s “long-term leadership in the obesity market.”
- “Best Stock for the Next 3 Years”: Analysts at Emerald Asset Management recently named Lilly one of the best stocks to buy and hold through 2029, pointing to positive Phase 3 “VIVID-2” data as a catalyst for sustained outperformance.
- Goldman Sachs Growth Pick: Lilly remains a top growth pick for Goldman Sachs, which highlights the company’s “innovation-driven” pipeline as a shield against broader market volatility.
3. Insider Trading: Major Charitable & Tactical Trimming
With the stock trading above $1,100 in early January 2026, the activity has been dominated by massive volume from the company’s primary endowment and tactical sales from the executive team.
- Lilly Endowment Inc: Executed a series of massive sales on January 7, 2026, totaling over 23,000 shares at prices ranging from $1,112 to $1,116, representing tens of millions in proceeds. This is a common pattern for the endowment to fund its charitable operations.
- The 2025 “Buy” Signal: It is worth noting that several top executives, including CEO David Ricks, CFO Lucas Montarce, and Chief Scientific Officer Daniel Skovronsky, were net buyers of the stock in August 2025 at prices between $634 and $691. Those internal investments have now gained nearly 60% in value.
- Active Roster: Nearly the entire senior leadership team (including the Presidents of Oncology, Immunology, and Neuroscience) has been active in February 2026, suggesting a period of high-level equity rebalancing following year-end results.
Summary Verdict
Eli Lilly is currently a “Consensus Institutional Powerhouse.” The 641% increase from Marshall Wace and the $1,350 price target from Barclays suggest that professional managers believe the stock is a “generational” winner in the pharmaceutical space. While the Lilly Endowment and some insiders are trimming positions at record highs ($1,100+), the aggressive buying from the “smart money” confirms that Lilly is the definitive play for the 2026-2029 metabolic health boom.
